← Back to Search

Genetic Sequencing

Genome Sequencing for Personalized Cancer Therapy

N/A
Recruiting
Led By Janessa J Laskin, MD
Research Sponsored by British Columbia Cancer Agency
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
ECOG PS 0 or 1
Age >/= 18 years
Must not have
Unwilling to receive medically actionable findings (germline and/or somatic)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial will use full genome sequencing to identify cancer "drivers" and corresponding drugs that may inhibit these pathways, in order to match each individual cancer to a biologically relevant targeted therapy.

Who is the study for?
This trial is for adults with cancer who can provide tissue samples, have a life expectancy of at least 6 months, and are fit enough to potentially participate in future clinical trials. They must be willing to share their genomic data and understand it may guide treatment options.
What is being tested?
The trial uses full genome sequencing on individual cancers to identify 'drivers' of the disease and match them with targeted therapies that could inhibit these pathways. It aims to personalize cancer treatment based on genetic analysis.
What are the potential side effects?
Since this trial involves genome sequencing rather than drug interventions, traditional side effects are not applicable. However, there might be risks associated with biopsy procedures or psychological impact from learning about one's genomic information.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am fully active or restricted in physically strenuous activity but can do light work.
Select...
I am 18 years old or older.
Select...
I can provide a recent biopsy or have suitable stored tissue samples for the study.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I do not want to know about specific genetic findings from my tests.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Cataloging of cancer genomes
Influence of genomic data on clinical decision-making

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Genome SequencingExperimental Treatment1 Intervention
There is only one arm to this study.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Genome sequencing
2017
N/A
~10

Find a Location

Who is running the clinical trial?

British Columbia Cancer AgencyLead Sponsor
175 Previous Clinical Trials
89,228 Total Patients Enrolled
BC Cancer FoundationOTHER
18 Previous Clinical Trials
3,559 Total Patients Enrolled
Janessa J Laskin, MDPrincipal InvestigatorBritish Columbia Cancer Agency

Media Library

Genome sequencing (Genetic Sequencing) Clinical Trial Eligibility Overview. Trial Name: NCT02155621 — N/A
Cancer Research Study Groups: Genome Sequencing
Cancer Clinical Trial 2023: Genome sequencing Highlights & Side Effects. Trial Name: NCT02155621 — N/A
Genome sequencing (Genetic Sequencing) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02155621 — N/A
~438 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top